{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:46:46Z","timestamp":1790948806570,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Military Med Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis and treatment guidelines for clinicians caring for patients are needed. In the early stage, we have issued \u201cA rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)\u201d; now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline. We formed a working group of clinical experts and methodologists. The steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas: chemoprophylaxis, diagnosis, treatments, and discharge management. We searched the literature for direct evidence on the management of COVID-19, and assessed its certainty generated recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Recommendations were either strong or weak, or in the form of ungraded consensus-based statement. Finally, we issued 34 statements. Among them, 6 were strong recommendations for, 14 were weak recommendations for, 3 were weak recommendations against and 11 were ungraded consensus-based statement. They covered topics of chemoprophylaxis (including agents and Traditional Chinese Medicine (TCM) agents), diagnosis (including clinical manifestations, reverse transcription-polymerase chain reaction (RT-PCR), respiratory tract specimens, IgM and IgG antibody tests, chest computed tomography, chest x-ray, and CT features of asymptomatic infections), treatments (including lopinavir-ritonavir, umifenovir, favipiravir, interferon, remdesivir, combination of antiviral drugs, hydroxychloroquine\/chloroquine, interleukin-6 inhibitors, interleukin-1 inhibitors, glucocorticoid, qingfei paidu decoction, lianhua qingwen granules\/capsules, convalescent plasma, lung transplantation, invasive or noninvasive ventilation, and extracorporeal membrane oxygenation (ECMO)), and discharge management (including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge). We also created two figures of these recommendations for the implementation purpose. We hope these recommendations can help support healthcare workers caring for COVID-19 patients.<\/jats:p>","DOI":"10.1186\/s40779-020-00270-8","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T08:03:49Z","timestamp":1599206629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)"],"prefix":"10.1016","volume":"7","author":[{"given":"Ying-Hui","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yuan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun-Tao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Rong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Dong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Li","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Can","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Chi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Xian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Fu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Sha","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Ru","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-725X","authenticated-orcid":false,"given":"Xian-Tao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Shun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Chinese Research Hospital Association (CRHA)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"270_CR1","unstructured":"WHO. WHO coronavirus disease (covid-19) dashboard. https:\/\/covid19.who.int\/. Accessed 31 July 2020."},{"issue":"1","key":"270_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-0233-6","volume":"7","author":"YH Jin","year":"2020","unstructured":"Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. https:\/\/doi.org\/10.1186\/s40779-020-0233-6.","journal-title":"Mil Med Res"},{"issue":"5","key":"270_CR3","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1371\/journal.pmed.0040119","volume":"4","author":"HJ Sch\u00fcnemann","year":"2007","unstructured":"Sch\u00fcnemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, et al. Transparent development of the WHO rapid advice guidelines. PLoS Med. 2007;4(5):e119. https:\/\/doi.org\/10.1371\/journal.pmed.0040119.","journal-title":"PLoS Med"},{"issue":"3","key":"270_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.12173\/j.issn.1004-5511","volume":"30","author":"YH Jin","year":"2020","unstructured":"Jin YH, Li HJ, Zhan QY, Peng ZY, F YY, Cai L, et al. Evidence-based Chinese expert recommendations on drug prevention, diagnosis, treatment, and discharge management of COVID-19: a protocol. Yixue Xinzhi Zazhi. 2020;30(3):209\u201326 https:\/\/doi.org\/10.12173\/j.issn.1004-5511.","journal-title":"Yixue Xinzhi Zazhi"},{"issue":"1","key":"270_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","volume":"7","author":"LL Ma","year":"2020","unstructured":"Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7. https:\/\/doi.org\/10.1186\/s40779-020-00238-8.","journal-title":"Mil Med Res"},{"key":"270_CR6","unstructured":"Cochrane Training. Grade handbook. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed 10 Mar 2020."},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"i2016","DOI":"10.1136\/bmj.i2016","volume":"353","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Sch\u00fcnemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016. https:\/\/doi.org\/10.1136\/bmj.i2016.","journal-title":"BMJ"},{"key":"270_CR8","doi-asserted-by":"publisher","first-page":"i2089","DOI":"10.1136\/bmj.i2089","volume":"353","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089. https:\/\/doi.org\/10.1136\/bmj.i2089.","journal-title":"BMJ"},{"key":"270_CR9","unstructured":"EQUATOR Network. The agree reporting checklist: A tool to improve reporting of clinical practice guidelines https:\/\/www.equator-network.org\/reporting-guidelines\/the-agree-reporting-checklist-a-tool-to-improve-reporting-of-clinical-practice-guidelines\/. Accessed 7 Apr 2020."},{"key":"270_CR10","unstructured":"A Reporting tool for Practice Guidelines in Health Care: The RIGHT Statement [https:\/\/www.equator-network.org\/reporting-guidelines\/right-statement\/]. Accessed 18 June 2020."},{"key":"270_CR11","doi-asserted-by":"publisher","unstructured":"Bhattacharya R, Chowdhury S, Mukherjee R, Nandi A, Kulshrestha M, Ghosh R, et al. Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers - a Retrospective cohort. medRxiv. 2020:2020.2006.2009.20116806 https:\/\/doi.org\/10.1101\/2020.06.09.20116806.","DOI":"10.1101\/2020.06.09.20116806"},{"key":"270_CR12","doi-asserted-by":"publisher","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2016638.","DOI":"10.1056\/NEJMoa2016638"},{"issue":"3","key":"270_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11596-020-2203-3","volume":"40","author":"JN Zhang","year":"2020","unstructured":"Zhang JN, Wang WJ, Peng B, Peng W, Zhang YS, Wang YL, et al. Potential of Arbidol for post-exposure prophylaxis of COVID-19 transmission: a preliminary report of a retrospective cohort study. Curr Med Sci. 2020;40(3):480\u20135. https:\/\/doi.org\/10.1007\/s11596-020-2203-3.","journal-title":"Curr Med Sci"},{"key":"270_CR14","doi-asserted-by":"publisher","unstructured":"Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol. 2020; https:\/\/doi.org\/10.1002\/jmv.25884.","DOI":"10.1002\/jmv.25884"},{"issue":"6","key":"270_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234765","volume":"15","author":"MC Grant","year":"2020","unstructured":"Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765. https:\/\/doi.org\/10.1371\/journal.pone.0234765.","journal-title":"PLoS One"},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fmed.2020.00295","volume":"7","author":"J Koh","year":"2020","unstructured":"Koh J, Shah SU, Chua PEY, Gui H, Pang J. Epidemiological and clinical characteristics of cases during the early phase of COVID-19 pandemic: a systematic review and Meta-analysis. Front Med (Lausanne). 2020;7:295. https:\/\/doi.org\/10.3389\/fmed.2020.00295.","journal-title":"Front Med (Lausanne)"},{"key":"270_CR17","doi-asserted-by":"publisher","unstructured":"Rodriguez-Morales AJ, Cardona-Ospina JA, Guti\u00e9rrez-Ocampo E, Villamizar-Pe\u00f1a R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020:101623. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101623.","DOI":"10.1016\/j.tmaid.2020.101623"},{"key":"270_CR18","doi-asserted-by":"publisher","unstructured":"Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25757.","DOI":"10.1002\/jmv.25757"},{"key":"270_CR19","doi-asserted-by":"publisher","unstructured":"Sun PF, Qie SY, Liu ZJ, Ren JZ, Li K, Xi JN. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25735.","DOI":"10.1002\/jmv.25735"},{"key":"270_CR20","doi-asserted-by":"publisher","unstructured":"Cao YH, Liu XL, Xiong LJ, Cai KL. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25822.","DOI":"10.1002\/jmv.25822"},{"key":"270_CR21","doi-asserted-by":"publisher","unstructured":"Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Inf Secur. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.041.","DOI":"10.1016\/j.jinf.2020.03.041"},{"issue":"2","key":"270_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.21053\/ceo.2020.00570","volume":"13","author":"JH Park","year":"2020","unstructured":"Park JH, Jang W, Kim SW, Lee J, Lim YS, Cho CG, et al. The clinical manifestations and chest computed tomography findings of coronavirus disease 2019 (COVID-19) patients in China: a proportion Meta-analysis. Clin Exp Otorhinolaryngol. 2020;13(2):95\u2013105. https:\/\/doi.org\/10.21053\/ceo.2020.00570.","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"270_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","volume":"94","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91\u20135. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.017.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"270_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.20524\/aog.2020.0506","volume":"33","author":"T Rokkas","year":"2020","unstructured":"Rokkas T. Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. Ann Gastroenterol. 2020;33(4):355\u201365. https:\/\/doi.org\/10.20524\/aog.2020.0506.","journal-title":"Ann Gastroenterol"},{"issue":"7","key":"270_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/s2468-1253(20)30126-6","volume":"5","author":"R Mao","year":"2020","unstructured":"Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667\u201378. https:\/\/doi.org\/10.1016\/s2468-1253(20)30126-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"270_CR26","doi-asserted-by":"publisher","unstructured":"Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and Meta-analysis. Gastroenterology. 2020. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.065.","DOI":"10.1053\/j.gastro.2020.03.065"},{"key":"270_CR27","doi-asserted-by":"publisher","unstructured":"Suresh Kumar VC, Mukherjee S, Harne PS, Subedi A, Ganapathy MK, Patthipati VS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020;7(1). https:\/\/doi.org\/10.1136\/bmjgast-2020-000417.","DOI":"10.1136\/bmjgast-2020-000417"},{"key":"270_CR28","doi-asserted-by":"publisher","unstructured":"Li J, He X, Yuanyuan ZW, Li X, Zhang Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2020. https:\/\/doi.org\/10.1016\/j.ajic.2020.06.008.","DOI":"10.1016\/j.ajic.2020.06.008"},{"issue":"9","key":"270_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.21037\/atm-20-2124","volume":"8","author":"D Huang","year":"2020","unstructured":"Huang D, Lian X, Song F, Ma H, Lian Z, Liang Y, et al. Clinical features of severe patients infected with 2019 novel coronavirus: a systematic review and meta-analysis. Ann Transl Med. 2020;8(9):576. https:\/\/doi.org\/10.21037\/atm-20-2124.","journal-title":"Ann Transl Med"},{"key":"270_CR30","unstructured":"Li X, Feng AZ, Ma W, Lyu J, Xu AD. Traditional Chinese medicine syndromes of the novel Coronavious Pneumonica: a systemic review and Meta analysis. World Chin Med. 2020:1\u20136."},{"key":"270_CR31","doi-asserted-by":"publisher","unstructured":"Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis. 2020. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.052.","DOI":"10.1016\/j.ijid.2020.06.052"},{"key":"270_CR32","doi-asserted-by":"publisher","unstructured":"Borsetto D, Hopkins C, Philips V, Obholzer R, Tirelli G, Polesel J, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology. 2020. https:\/\/doi.org\/10.4193\/Rhin20.185.","DOI":"10.4193\/Rhin20.185"},{"key":"270_CR33","doi-asserted-by":"publisher","unstructured":"Von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.15.20132134.","DOI":"10.1101\/2020.06.15.20132134"},{"key":"270_CR34","doi-asserted-by":"publisher","unstructured":"Hoang MP, Kanjanaumporn J, Aeumjaturapat S, Chusakul S, Seresirikachorn K, Snidvongs K. Olfactory and gustatory dysfunctions in COVID-19 patients: a systematic review and meta-analysis. Asian Pac J Allergy Immunol. 2020. https:\/\/doi.org\/10.12932\/ap-210520-0853.","DOI":"10.12932\/ap-210520-0853"},{"key":"270_CR35","doi-asserted-by":"publisher","unstructured":"Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, et al. Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol. 2020. https:\/\/doi.org\/10.1111\/aos.14472.","DOI":"10.1111\/aos.14472"},{"key":"270_CR36","doi-asserted-by":"publisher","unstructured":"Zhou Y, Duan C, Zeng Y, Tong Y, Nie Y, Yang Y, et al. Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients. Ophthalmology. 2020. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.028.","DOI":"10.1016\/j.ophtha.2020.04.028"},{"key":"270_CR37","doi-asserted-by":"publisher","unstructured":"Hong N, Yu W, Xia J, Shen Y, Yap M, Han W. Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19. Acta Ophthalmol. 2020. https:\/\/doi.org\/10.1111\/aos.14445.","DOI":"10.1111\/aos.14445"},{"issue":"5","key":"270_CR38","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamaophthalmol.2020.1291","volume":"138","author":"P Wu","year":"2020","unstructured":"Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5):575\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.1291.","journal-title":"JAMA Ophthalmol"},{"key":"270_CR39","doi-asserted-by":"publisher","unstructured":"Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16778.","DOI":"10.1111\/jdv.16778"},{"key":"270_CR40","doi-asserted-by":"publisher","unstructured":"Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li J. SARS-CoV-2 Detection in Different Respiratory Sites: A Systematic Review and Meta-Analysis. medRxiv. 2020:2020.2005.2014.20102038 https:\/\/doi.org\/10.1101\/2020.05.14.20102038.","DOI":"10.1101\/2020.05.14.20102038"},{"key":"270_CR41","first-page":"341","volume":"04","author":"M Wang","year":"2020","unstructured":"Wang M, Wu Q, Xu W, Qiao B, Wang J, Chen Z, et al. Analysis of 8274 cases of new coronavirus nucleic acid detection and co-infection in Wuhan. Chin J Laboratory Med. 2020;04:341\u20135.","journal-title":"Chin J Laboratory Med"},{"key":"270_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cca.2020.03.009","volume":"505","author":"R Liu","year":"2020","unstructured":"Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020;505:172\u20135. https:\/\/doi.org\/10.1016\/j.cca.2020.03.009.","journal-title":"Clin Chim Acta"},{"key":"270_CR43","doi-asserted-by":"publisher","first-page":"Cd013652","DOI":"10.1002\/14651858.cd013652","volume":"6","author":"JJ Deeks","year":"2020","unstructured":"Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:Cd013652. https:\/\/doi.org\/10.1002\/14651858.cd013652.","journal-title":"Cochrane Database Syst Rev"},{"key":"270_CR44","doi-asserted-by":"publisher","unstructured":"Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. Radiology. 2020:201343. https:\/\/doi.org\/10.1148\/radiol.2020201343.","DOI":"10.1148\/radiol.2020201343"},{"issue":"4","key":"270_CR45","doi-asserted-by":"publisher","first-page":"W105","DOI":"10.1097\/rti.0000000000000533","volume":"35","author":"S Schiaffino","year":"2020","unstructured":"Schiaffino S, Tritella S, Cozzi A, Carriero S, Blandi L, Ferraris L, et al. Diagnostic performance of chest X-ray for COVID-19 pneumonia during the SARS-CoV-2 pandemic in Lombardy, Italy. J Thorac Imaging. 2020;35(4):W105\u2013w106. https:\/\/doi.org\/10.1097\/rti.0000000000000533.","journal-title":"J Thorac Imaging"},{"key":"270_CR46","first-page":"E014","volume":"00","author":"Z Deng","year":"2020","unstructured":"Deng Z, Zhang X, Li Y, Xu H, Gang Y, Wang H, et al. Value of chest CT screening in the early COVID-19 outbreak. Chin J Radiol. 2020;00:E014.","journal-title":"Chin J Radiol"},{"key":"270_CR47","doi-asserted-by":"publisher","unstructured":"Zheng Y, Wang L, Ben S. Meta-analysis of chest CT features of patients with COVID-19 pneumonia. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26218.","DOI":"10.1002\/jmv.26218"},{"issue":"4","key":"270_CR48","doi-asserted-by":"publisher","first-page":"e2112","DOI":"10.1002\/rmv.2112","volume":"30","author":"A Pormohammad","year":"2020","unstructured":"Pormohammad A, Ghorbani S, Khatami A, Farzi R, Baradaran B, Turner DL, et al. Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis. Rev Med Virol. 2020;30(4):e2112. https:\/\/doi.org\/10.1002\/rmv.2112.","journal-title":"Rev Med Virol"},{"key":"270_CR49","doi-asserted-by":"publisher","unstructured":"Altmayer S, Zanon M, Pacini GS, Watte G, Barros MC, Mohammed TL, et al. Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis. Eur Radiol. 2020:1\u201312. https:\/\/doi.org\/10.1007\/s00330-020-07018-x.","DOI":"10.1007\/s00330-020-07018-x"},{"key":"270_CR50","doi-asserted-by":"publisher","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2001282.","DOI":"10.1056\/NEJMoa2001282"},{"key":"270_CR51","doi-asserted-by":"publisher","unstructured":"Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI). medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.19.20038984.","DOI":"10.1101\/2020.03.19.20038984"},{"key":"270_CR52","doi-asserted-by":"publisher","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007.","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"270_CR53","unstructured":"Yu AR, Fan X, Zhao Y, Zhou F, Zhao LL, Liu J, et al. Retrospective study of the clinical efficacy and safety of Lopinavir\/ritonavir combined with other antiviral in the treatment of coronavirus disease (COVID-19). Herald Med. 2020:1\u201312."},{"key":"270_CR54","doi-asserted-by":"publisher","unstructured":"Yan D, Liu X-y, Zhu Y-n, Huang L, Dan B-t, Zhang G-j, et al. Factors associated with prolonged viral shedding and impact of Lopinavir\/Ritonavir treatment in patients with SARS-CoV-2 infection. Eur Respir J. 2020:2020.2003.2022.20040832 https:\/\/doi.org\/10.1101\/2020.03.22.20040832.","DOI":"10.1101\/2020.03.22.20040832"},{"issue":"6","key":"270_CR55","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.26355\/eurrev_202003_20706","volume":"24","author":"XT Ye","year":"2020","unstructured":"Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390\u20136. https:\/\/doi.org\/10.26355\/eurrev_202003_20706.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"270_CR56","doi-asserted-by":"publisher","unstructured":"Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19. J Inf Secur. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.060.","DOI":"10.1016\/j.jinf.2020.03.060"},{"issue":"00","key":"270_CR57","doi-asserted-by":"publisher","first-page":"E008","DOI":"10.3760\/cma.j.cn311365-20200210-00050","volume":"38","author":"J Chen","year":"2020","unstructured":"Chen J, Ling Y, Xi XH, Liu P, Li F, Li T, et al. Efficacies of lopinavir\/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis. 2020;38(00):E008. https:\/\/doi.org\/10.3760\/cma.j.cn311365-20200210-00050.","journal-title":"Chin J Infect Dis"},{"key":"270_CR58","doi-asserted-by":"crossref","unstructured":"Xu KJ, Chen YF, Yuan J, Yi P, Ding C, Wu WR, et al. Clinical efficacy of Arbidol in patients with 2019 Novel Coronavirus-Infected pneumonia: A retrospective cohort study. 2020. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3542148.","DOI":"10.2139\/ssrn.3542148"},{"key":"270_CR59","doi-asserted-by":"publisher","unstructured":"Chen W, Yao M, Fang Z, Lv X, Deng M, Wu Z. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26142.","DOI":"10.1002\/jmv.26142"},{"issue":"7","key":"270_CR60","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","volume":"26","author":"N Lian","year":"2020","unstructured":"Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917\u201321. https:\/\/doi.org\/10.1016\/j.cmi.2020.04.026.","journal-title":"Clin Microbiol Infect"},{"key":"270_CR61","doi-asserted-by":"publisher","unstructured":"Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"270_CR62","doi-asserted-by":"publisher","unstructured":"Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial. Antimicrob Agents Chemother. 2020:2020.2005.2028.20116467. https:\/\/doi.org\/10.1101\/2020.05.28.20116467.","DOI":"10.1101\/2020.05.28.20116467"},{"key":"270_CR63","doi-asserted-by":"publisher","unstructured":"Estebanez M, Ramirez-Olivencia G, Mata T, Marti D, Gutierrez C, De Dios B, et al. Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study. medRxiv. 2020:2020.2005.2015.20084293. https:\/\/doi.org\/10.1101\/2020.05.15.20084293.","DOI":"10.1101\/2020.05.15.20084293"},{"key":"270_CR64","doi-asserted-by":"publisher","unstructured":"Pereda R, Gonzalez D, Rivero H, Rivero J, Perez A, LdR L, et al. Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience. medRxiv. 2020:2020.2005.2029.20109199. https:\/\/doi.org\/10.1101\/2020.05.29.20109199.","DOI":"10.1101\/2020.05.29.20109199"},{"key":"270_CR65","doi-asserted-by":"publisher","unstructured":"Zhou Q, Wei X-S, Xiang X, Wang X, Wang Z-H, Chen V, et al. Interferon-a2b treatment for COVID-19. medRxiv. 2020:2020.2004.2006.20042580. https:\/\/doi.org\/10.1101\/2020.04.06.20042580.","DOI":"10.1101\/2020.04.06.20042580"},{"key":"270_CR66","doi-asserted-by":"publisher","unstructured":"Roshanshad A, Kamalipour A, Ashraf MA, Roshanshad R, Akbari M. Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic Review. medRxiv. 2020:2020.2006.2015.20131227. https:\/\/doi.org\/10.1101\/2020.06.15.20131227.","DOI":"10.1101\/2020.06.15.20131227"},{"issue":"10238","key":"270_CR67","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/s0140-6736(20)31042-4","volume":"395","author":"IF Hung","year":"2020","unstructured":"Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695\u2013704. https:\/\/doi.org\/10.1016\/s0140-6736(20)31042-4.","journal-title":"Lancet"},{"key":"270_CR68","first-page":"E010","volume":"00","author":"R Wei","year":"2020","unstructured":"Wei R, Zheng N, Jiang X, Ma C, Xu X, Liu S, et al. Early antiviral therapy of abidor combined with lopinavir\/ritonavir and re-combinant interferon\u03b1-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study. Chin J Clin Infect Dis. 2020;00:E010.","journal-title":"Chin J Clin Infect Dis"},{"key":"270_CR69","doi-asserted-by":"publisher","unstructured":"Lan X, Shao C, Zeng X, Wu Z, Xu Y. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study. medRxiv. 2020:2020.2004.2025.20079079. https:\/\/doi.org\/10.1101\/2020.04.25.20079079.","DOI":"10.1101\/2020.04.25.20079079"},{"issue":"1","key":"270_CR70","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","volume":"81","author":"L Deng","year":"2020","unstructured":"Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV\/r versus LPV\/r alone against Corona virus disease 2019: a retrospective cohort study. J Inf Secur. 2020;81(1):e1\u20135. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.002.","journal-title":"J Inf Secur"},{"issue":"4\u20135","key":"270_CR71","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.micinf.2020.05.012","volume":"22","author":"P Xu","year":"2020","unstructured":"Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X, et al. Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect. 2020;22(4\u20135):200\u20135. https:\/\/doi.org\/10.1016\/j.micinf.2020.05.012.","journal-title":"Microbes Infect"},{"key":"270_CR72","unstructured":"Wang YN, Suo T, Fan H, Zhao KC, Zou JJ, Wu DD, et al. Clinical efficacy of Lopinavir-Ritonavir combined with interferon alpha in COVID-19. Med J Wuhan Univ. 2020:1\u20135."},{"key":"270_CR73","doi-asserted-by":"publisher","unstructured":"Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K, Nischal N, et al. Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis. medRxiv. 2020:2020.2007.2004.20146381. https:\/\/doi.org\/10.1101\/2020.07.04.20146381.","DOI":"10.1101\/2020.07.04.20146381"},{"key":"270_CR74","doi-asserted-by":"publisher","unstructured":"Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/m20-2496.","DOI":"10.7326\/m20-2496"},{"key":"270_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849","volume":"369","author":"W Tang","year":"2020","unstructured":"Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https:\/\/doi.org\/10.1136\/bmj.m1849.","journal-title":"BMJ"},{"key":"270_CR76","doi-asserted-by":"publisher","unstructured":"Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection a randomized clinical trial. JAMA Netw Open. 2020;3(4). https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.8857.","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"270_CR77","doi-asserted-by":"publisher","unstructured":"Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Preprint. medRxiv. 2020. https:\/\/doi.org\/10.1016\/j.medj.2020.06.001.","DOI":"10.1016\/j.medj.2020.06.001"},{"key":"270_CR78","doi-asserted-by":"publisher","unstructured":"Boregowda U, Perisetti A, Nanjappa A, Gajendran M, Goyal H. Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis. medRxiv. 2020:2020.2007.2010.20150680. https:\/\/doi.org\/10.1101\/2020.07.10.20150680.","DOI":"10.1101\/2020.07.10.20150680"},{"key":"270_CR79","doi-asserted-by":"publisher","unstructured":"Carvalho V, Turon R, Goncalves B, Ceotto V, Kurtz P, Righy C. Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.13.20149328.","DOI":"10.1101\/2020.07.13.20149328"},{"key":"270_CR80","doi-asserted-by":"publisher","unstructured":"Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Inf Secur. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.07.008.","DOI":"10.1016\/j.jinf.2020.07.008"},{"key":"270_CR81","doi-asserted-by":"publisher","unstructured":"Rossi B, Nguyen LS, Zimmermann P, Boucenna F, Baucher L, Dubret L, et al. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.06.20122341.","DOI":"10.1101\/2020.06.06.20122341"},{"key":"270_CR82","doi-asserted-by":"publisher","unstructured":"Marfella R, Paolisso P, Sardu C, Bergamaschi L, D'Angelo EC, Barbieri M, et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020. https:\/\/doi.org\/10.1016\/j.diabet.2020.05.005.","DOI":"10.1016\/j.diabet.2020.05.005"},{"key":"270_CR83","doi-asserted-by":"publisher","unstructured":"Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218122.","DOI":"10.1136\/annrheumdis-2020-218122"},{"key":"270_CR84","doi-asserted-by":"publisher","unstructured":"Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. 2020:2020.2004.2001.20048561. https:\/\/doi.org\/10.1101\/2020.04.01.20048561.","DOI":"10.1101\/2020.04.01.20048561"},{"issue":"7","key":"270_CR85","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","volume":"2","author":"T Huet","year":"2020","unstructured":"Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393\u2013400. https:\/\/doi.org\/10.1016\/S2665-9913(20)30164-8.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"270_CR86","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/s2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325\u201331. https:\/\/doi.org\/10.1016\/s2665-9913(20)30127-2.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"270_CR87","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.dsx.2020.06.054","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a Clinician's perspective. Diabetes Metab Syndr. 2020;14(5):971\u20138. https:\/\/doi.org\/10.1016\/j.dsx.2020.06.054.","journal-title":"Diabetes Metab Syndr"},{"key":"270_CR88","doi-asserted-by":"publisher","unstructured":"Wang D, Wang J, Jiang Q, Yang J, Li J, Gao C, et al. No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study. medRxiv. 2020:2020.2004.2021.20066258. https:\/\/doi.org\/10.1101\/2020.04.21.20066258.","DOI":"10.1101\/2020.04.21.20066258"},{"key":"270_CR89","doi-asserted-by":"publisher","first-page":"E009","DOI":"10.3760\/cma.j.cn115673\u204320200225\u204300072","volume":"00","author":"Q Ni","year":"2020","unstructured":"Ni Q, Ding C, Li YT, Zhao H, Liu J, Zhang X, et al. Retrospective analysis of medium and low dose glucocorticoids on viral clearance in patients with new coronavirus pneumonia. Chin J Clin Infect Dis. 2020;00:E009. https:\/\/doi.org\/10.3760\/cma.j.cn115673\u204320200225\u204300072.","journal-title":"Chin J Clin Infect Dis"},{"key":"270_CR90","doi-asserted-by":"publisher","unstructured":"Majmundar M, Kansara T, Lenik JM, Park H, Ghosh K, Doshi R, et al. Efficacy of Corticosteroids in Non-Intensive Care Unit Patients with COVID-19 Pneumonia from the New York Metropolitan region. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.02.20145565.","DOI":"10.1101\/2020.07.02.20145565"},{"key":"270_CR91","doi-asserted-by":"publisher","unstructured":"Corral L, Bahamonde A, Arnaiz delas Revillas F, Gomez-Barquero J, Abadia-Otero J, Garcia-Ibarbia C, et al. A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.17.20133579.","DOI":"10.1101\/2020.06.17.20133579"},{"key":"270_CR92","doi-asserted-by":"publisher","unstructured":"Yuan M, Xu X, Xia D, Tao Z, Yin W, Tan W, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock. 2020. https:\/\/doi.org\/10.1097\/SHK.0000000000001574.","DOI":"10.1097\/SHK.0000000000001574"},{"key":"270_CR93","doi-asserted-by":"publisher","unstructured":"Fernandez Cruz A, Ruiz-Antoran B, Munoz Gomez A, Sancho Lopez A, Mills Sanchez P, Centeno Soto GA, et al. Impact of Glucocorticoid Treatment in Sars-Cov-2 Infection Mortality: A Retrospective Controlled Cohort Study. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.01168-20.","DOI":"10.1128\/AAC.01168-20"},{"key":"270_CR94","doi-asserted-by":"publisher","unstructured":"Salton F, Confalonieri P, Santus P, Harari S, Scala R, Lanini S, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.17.20134031.","DOI":"10.1101\/2020.06.17.20134031"},{"key":"270_CR95","doi-asserted-by":"publisher","unstructured":"Sanz Herrero F, Puchades Gimeno F, Ortega Garcia P, Ferrer Gomez C, Ocete Mochon MD, Garcia Deltoro M. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. J Intern Med. 2020. https:\/\/doi.org\/10.1111\/joim.13145.","DOI":"10.1111\/joim.13145"},{"issue":"08","key":"270_CR96","first-page":"2046","volume":"51","author":"KY Li","year":"2020","unstructured":"Li KY, An W, Xia F, Chen M, Yang P, Liao YL, et al. Observation on clinical effect of modified Qingfei Paidu decoction in treatment of COVID-19. Chin Tradit Herbal Drugs. 2020;51(08):2046\u20139.","journal-title":"Chin Tradit Herbal Drugs"},{"key":"270_CR97","unstructured":"Yu P, Li YZ, Wan SB, Wang Y. Effects of Lianhua Qingwen Granules plus Arbidol on treatment of mild corona virus disease-19. 2020;55(12):1042\u20135. http:\/\/journal11.magtechjournal.com\/Jwk_zgyxzz\/CN\/abstract\/abstract32710.shtml."},{"key":"270_CR98","doi-asserted-by":"publisher","unstructured":"Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2020:153242. https:\/\/doi.org\/10.1016\/j.phymed.2020.153242.","DOI":"10.1016\/j.phymed.2020.153242"},{"key":"270_CR99","unstructured":"Cheng DZ, Wang WJ, Li Y, Wu XD, Zhou B, Song QY. Analysis of 51 cases of COVID-19 treated with traditional Chinese medicine Lianhua Qingwen: a multicenter retrospective study. Tianjin J Tradit Chin Med. 2020:1\u20136."},{"key":"270_CR100","doi-asserted-by":"publisher","unstructured":"Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective Clinical Analysis on Treatment of Coronavirus Disease 2019 with Traditional Chinese Medicine Lianhua Qingwen. Chin J Exp Tradit Med Formulae. 2020:1\u20137. https:\/\/doi.org\/10.13422\/j.cnki.syfjx.20201099.","DOI":"10.13422\/j.cnki.syfjx.20201099"},{"key":"270_CR101","unstructured":"Lv RB, Wang WJ, Li X. Clinical observation of 63 suspected cases of COVID-19 treated by Chinese medicine lianhua clearing disease. J Tradit Chin Med. 2020. http:\/\/kns.cnki.net\/kcms\/detail\/11.2166.R.20200215.1633.004.html."},{"key":"270_CR102","doi-asserted-by":"publisher","first-page":"Cd013600","DOI":"10.1002\/14651858.CD013600.pub2","volume":"7","author":"V Piechotta","year":"2020","unstructured":"Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7:Cd013600. https:\/\/doi.org\/10.1002\/14651858.CD013600.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"270_CR103","doi-asserted-by":"crossref","unstructured":"Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv. 2020. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.01.20139857v1.","DOI":"10.1101\/2020.07.01.20139857"},{"key":"270_CR104","doi-asserted-by":"crossref","unstructured":"Rasheed AM, Ftak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et al. The therapeutic effectiveness of convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv. 2020. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.24.20121905v2.","DOI":"10.1101\/2020.06.24.20121905"},{"issue":"12","key":"270_CR105","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/cm9.0000000000000839","volume":"133","author":"JY Chen","year":"2020","unstructured":"Chen JY, Qiao K, Liu F, Wu B, Xu X, Jiao GQ, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J. 2020;133(12):1390\u20136. https:\/\/doi.org\/10.1097\/cm9.0000000000000839.","journal-title":"Chin Med J"},{"issue":"1","key":"270_CR106","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1097\/sla.0000000000003955","volume":"272","author":"W Han","year":"2020","unstructured":"Han W, Zhu M, Chen J, Zhang J, Zhu S, Li T, et al. Lung transplantation for elderly patients with end-stage COVID-19 pneumonia. Ann Surg. 2020;272(1):e33\u20134. https:\/\/doi.org\/10.1097\/sla.0000000000003955.","journal-title":"Ann Surg"},{"issue":"5","key":"270_CR107","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1631\/jzus.B2000182","volume":"21","author":"TM Xuan","year":"2020","unstructured":"Xuan TM, Wang XX, Pu XY, Han WL, Guo XG. Primary percutaneous coronary intervention in a COVID-19 patient with ST-segment elevation myocardial infarction after lung transplantation: a case report. J Zhejiang Univ Sci B. 2020;21(5):411\u20135. https:\/\/doi.org\/10.1631\/jzus.B2000182.","journal-title":"J Zhejiang Univ Sci B"},{"key":"270_CR108","doi-asserted-by":"publisher","unstructured":"Wong J, Koh WC, Momin RN, Alikhan MF, Fadillah N, Naing L. Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: evidence from Brunei Darussalam. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26199.","DOI":"10.1002\/jmv.26199"},{"key":"270_CR109","doi-asserted-by":"publisher","unstructured":"Lu J, Peng J, Xiong Q, Liu Z, Lin H, Tan X, et al. Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. medRxiv. 2020:2020.2006.2015.20131748. https:\/\/doi.org\/10.1101\/2020.06.15.20131748.","DOI":"10.1101\/2020.06.15.20131748"},{"key":"270_CR110","doi-asserted-by":"publisher","unstructured":"Yang C, Jiang M, Wang X, Tang X, Fang S, Li H, et al. Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study. medRxiv. 2020:2020.2007.2021.20125138. https:\/\/doi.org\/10.1101\/2020.07.21.20125138.","DOI":"10.1101\/2020.07.21.20125138"},{"key":"270_CR111","doi-asserted-by":"publisher","unstructured":"Su Y, Zhu L-S, Gao Y, Li Y, Xiong Z, Hu B, et al. Clinical characteristics of Covid-19 patients with re-positive test results: an observational study. medRxiv. 2020:2020.2006.2023.20138149. https:\/\/doi.org\/10.1101\/2020.06.23.20138149.","DOI":"10.1101\/2020.06.23.20138149"},{"key":"270_CR112","doi-asserted-by":"publisher","unstructured":"An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.26.20044222.","DOI":"10.1101\/2020.03.26.20044222"},{"issue":"7","key":"270_CR113","doi-asserted-by":"publisher","first-page":"e23392","DOI":"10.1002\/jcla.23392","volume":"34","author":"H Zhu","year":"2020","unstructured":"Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19 convalescent patients with re-positive nucleic acid detection. J Clin Lab Anal. 2020;34(7):e23392. https:\/\/doi.org\/10.1002\/jcla.23392.","journal-title":"J Clin Lab Anal"},{"key":"270_CR114","doi-asserted-by":"publisher","unstructured":"Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. PCR assays turned positive in 25 discharged COVID-19 patients. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa398.","DOI":"10.1093\/cid\/ciaa398"},{"key":"270_CR115","doi-asserted-by":"publisher","unstructured":"Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J. 2020. https:\/\/doi.org\/10.1097\/cm9.0000000000000774.","DOI":"10.1097\/cm9.0000000000000774"},{"key":"270_CR116","doi-asserted-by":"publisher","unstructured":"Mei Q, Li J, Du R, Yuan X, Li M, Li J. Assessment of patients who tested positive for COVID-19 after recovery. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/s1473-3099(20)30433-3.","DOI":"10.1016\/s1473-3099(20)30433-3"},{"issue":"5","key":"270_CR117","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10475","volume":"3","author":"R Hu","year":"2020","unstructured":"Hu R, Jiang Z, Gao H, Huang D, Jiang D, Chen F, et al. Recurrent positive reverse transcriptase-polymerase chain reaction results for coronavirus disease 2019 in patients discharged from a Hospital in China. JAMA Netw Open. 2020;3(5):e2010475. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.10475.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"270_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2020.0156","volume":"81","author":"F Wu","year":"2020","unstructured":"Wu F, Zhang W, Zhang L, Wang D, Wan Y. Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again. Br J Hosp Med (Lond). 2020;81(4):1\u20132. https:\/\/doi.org\/10.12968\/hmed.2020.0156.","journal-title":"Br J Hosp Med (Lond)"},{"key":"270_CR119","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fmed.2020.00242","volume":"7","author":"LL Ma","year":"2020","unstructured":"Ma LL, Li BH, Jin YH, Deng T, Ren XQ, Zeng XT. Developments, evolution, and implications of National Diagnostic Criteria for COVID-19 in China. Front Med (Lausanne). 2020;7:242. https:\/\/doi.org\/10.3389\/fmed.2020.00242.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"270_CR120","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40779-020-00245-9","volume":"7","author":"YY Wang","year":"2020","unstructured":"Wang YY, Jin YH, Ren XQ, Li YR, Zhang XC, Zeng XT, et al. Updating the diagnostic criteria of COVID-19 \"suspected case\" and \"confirmed case\" is necessary. Mil Med Res. 2020;7(1):17. https:\/\/doi.org\/10.1186\/s40779-020-00245-9.","journal-title":"Mil Med Res"},{"key":"270_CR121","doi-asserted-by":"publisher","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020. https:\/\/doi.org\/10.1016\/s0140-6736(20)31604-4.","DOI":"10.1016\/s0140-6736(20)31604-4"},{"key":"270_CR122","doi-asserted-by":"publisher","unstructured":"Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020. https:\/\/doi.org\/10.1016\/s0140-6736(20)31605-6.","DOI":"10.1016\/s0140-6736(20)31605-6"},{"key":"270_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-020-00159-y","volume":"5","author":"M Gupta","year":"2020","unstructured":"Gupta M, Wahl B, Adhikari B, Bar-Zeev N, Bhandari S, Coria A, et al. The need for COVID-19 research in low- and middle-income countries. Glob Health Res Policy. 2020;5:33. https:\/\/doi.org\/10.1186\/s41256-020-00159-y.","journal-title":"Glob Health Res Policy"},{"key":"270_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-018-0084-9","volume":"3","author":"C Malla","year":"2018","unstructured":"Malla C, Aylward P, Ward P. Knowledge translation for public health in low- and middle- income countries: a critical interpretive synthesis. Glob Health Res Policy. 2018;3:29. https:\/\/doi.org\/10.1186\/s41256-018-0084-9.","journal-title":"Glob Health Res Policy"},{"issue":"3","key":"270_CR125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/jebm.12314","volume":"11","author":"SL Norris","year":"2018","unstructured":"Norris SL. Meeting public health needs in emergencies\u2013World Health Organization guidelines. J Evid Based Med. 2018;11(3):133\u20135. https:\/\/doi.org\/10.1111\/jebm.12314.","journal-title":"J Evid Based Med"}],"container-title":["Military Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40779-020-00270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40779-020-00270-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40779-020-00270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:52:18Z","timestamp":1772830338000},"score":1,"resource":{"primary":{"URL":"https:\/\/mmrjournal.biomedcentral.com\/articles\/10.1186\/s40779-020-00270-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1186\/s40779-020-00270-8","relation":{},"ISSN":["2054-9369"],"issn-type":[{"value":"2054-9369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Figs.\u00a0\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      , and\n                      \n                      from existed clinical data from Zhongnan Hospital of Wuhan University, and also approved by the Committee for Ethical Affairs of this hospital and written informed consent was obtained from each participant ([No. 2020074]). No additional ethical approval is needed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No one reported having stock, being a consultant paid by companies or receiving research funding from companies that have an interest in the guideline. Zhen-Shun Cheng reported participating in or hosting a study of Remdesivir for COVID-19. Ya-Dong Gao reported participating in or hosting two studies of Enteric capsule with diammonium glycyrrhizate combined with vitamin C and hydroxychloroquine for COVID-19. Jian Xia reported participating in or hosting two studies of ECOM treatment for critical patients and a prediction model for COVID-19 prognosis. Qi-Wen Yang reported participating in or hosting a study of clinical evaluation of rapid nucleic acid detection kit. Xiao-Chun Zhang reported participating in or hosting a study of COVID-19 technical research and integrated application projects. Yu-Feng Yuan reported participating in or hosting three studies of Clinical course and prognosis, TCM treatment and rapid disinfection of medical items for COVID-19. Xun-Tao Yin reported participating in or hosting CT imaging diagnosis for COVID-19. Zhui Yu reported participating in or hosting study of treatment for critical COVID-19 patients. Hong-Jun Li reported participating in or hosting study of machine learning for radiology of COVID-19. Xing-Huan Wang leading the favipiravir randomized controlled trial and it was supported by the National Key Research and Development Program of China (2020YFC0844400); Xing-Huan Wang, Xian-Tao Zeng and Ying-Hui Jin reported research projects involving infection of healthcare workers during this epidemic, which was supported by Special Project for Emergency of Hubei Province (2020FCA008). No other disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}